Differential Activity of Type I Interferon Subtypes for Dendritic Cell Differentiation

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Garcin, Geneviève ^a   Bordat, Yann ^a   Chuchana, Paul ^b   Monneron, Danièle ^a   Law, Helen K W ^c   Piehler, Jacob ^d   Uzé, Gilles ^a  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR   (France)

^d UNIVERSITY OF OSNABRÜCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON; ALPHA2 INTERFERON; ALPHA21 INTERFERON; ALPHA8 INTERFERON; B7 ANTIGEN; BETA INTERFERON; CD14 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA ANTIGEN; HLA DR ANTIGEN; INTERFERON; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; OMEGA INTERFERON; RANTES; TRANSCRIPTOME; UNCLASSIFIED DRUG; CYTOKINE; RNA;

ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL STIMULATION; CONTROLLED STUDY; DENDRITIC CELL; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MONOCYTE; PHAGOCYTOSIS; POLARIZATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; TH1 CELL; TRANSCRIPTOMICS; CELL MEMBRANE; CELL PROLIFERATION; CHEMOTAXIS; CYTOLOGY; DNA MICROARRAY; METABOLISM; SIGNAL TRANSDUCTION;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL MEMBRANE; CELL PROLIFERATION; CHEMOTAXIS; CYTOKINES; DENDRITIC CELLS; GENE EXPRESSION PROFILING; HUMANS; INTERFERON TYPE I; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHAGOCYTOSIS; RNA; SIGNAL TRANSDUCTION; TH1 CELLS; TRANSCRIPTOME;

EID: 84874609233     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058465     Document Type: Article

References (46)

1. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, et al. (2007) Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6: 975-990.
2. Gough DJ, Messina NL, Clarke CJ, Johnstone RW, Levy DE, (2012) Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 36: 166-174.
3. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, et al. (2011) Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208: 1989-2003.
4. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, et al. (2011) Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 208: 2005-2016.
5. Coelho LF, Magno de Freitas Almeida G, Mennechet FJ, Blangy A, Uze G, (2005) Interferon-alpha and-beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proc Natl Acad Sci U S A 102: 11917-11922.
6. Kalie E, Jaitin DA, Podoplelova Y, Piehler J, Schreiber G, (2008) The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities. J Biol Chem 283: 32925-32936.
7. Francois-Newton V, Magno de Freitas Almeida G, Payelle-Brogard B, Monneron D, Pichard-Garcia L, et al. (2011) USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PLoS One 6: e22200.
8. Moraga I, Harari D, Schreiber G, Uze G, Pellegrini S, (2009) Receptor density is key to the alpha2/beta interferon differential activities. Mol Cell Biol 29: 4778-4787.
9. Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, et al. (2011) Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 146: 621-632.
10. Uze G, Schreiber G, Piehler J, Pellegrini S, (2007) The receptor of the type I interferon family. Curr Top Microbiol Immunol 316: 71-95.
11. Francois-Newton V, Livingstone M, Payelle-Brogard B, Uze G, Pellegrini S, (2012) USP18 establishes the transcriptional and anti-proliferative interferon alpha/beta differential. Biochem J 446: 509-516.
12. Manry J, Laval G, Patin E, Fornarino S, Itan Y, et al. (2011) Evolutionary genetic dissection of human interferons. J Exp Med 208: 2747-2759.
13. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, et al. (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354: 709-718.
14. Ferrantini M, Capone I, Belardelli F, (2007) Interferon-alpha and cancer: Mechanisms of action and new perspectives of clinical use. Biochimie 89: 884-893.
15. Lapenta C, Santini SM, Spada M, Donati S, Urbani F, et al. (2006) IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur J Immunol 36: 2046-2060.
16. Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, et al. (1998) Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 64: 358-367.
17. Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, et al. (2000) Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 191: 1777-1788.
18. Gresser I, Belardelli F, (2002) Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev 13: 111-118.
19. Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, et al. (2011) Type I IFNs control antigen retention and survival of CD8alpha(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol 186: 5142-5150.
20. Chuchana P, Marchand D, Nugoli M, Rodriguez C, Molinari N, et al. (2007) An adaptation of the LMS method to determine expression variations in profiling data. Nucleic Acids Res 35: e71.
21. Mellor AL, Munn DH, (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4: 762-774.
22. Santini SM, Lapenta C, Belardelli F, (2005) Type I interferons as regulators of the differentiation/activation of human dendritic cells: methods for the evaluation of IFN-induced effects. Methods Mol Med 116: 167-181.
23. Gauzzi MC, Purificato C, Donato K, Jin Y, Wang L, et al. (2005) Suppressive effect of 1alpha,25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J Immunol 174: 270-276.
24. Parlato S, Santini SM, Lapenta C, Di Pucchio T, Logozzi M, et al. (2001) Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 98: 3022-3029.
25. Poon IK, Hulett MD, Parish CR, (2010) Molecular mechanisms of late apoptotic/necrotic cell clearance. Cell Death Differ 17: 381-397.
26. Wang Y, Swiecki M, Cella M, Alber G, Schreiber RD, et al. (2012) Timing and Magnitude of Type I Interferon Responses by Distinct Sensors Impact CD8 T Cell Exhaustion and Chronic Viral Infection. Cell Host Microbe 11: 631-642.
27. Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, et al. (2003) Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 4: 1009-1015.
28. Le Bon A, Tough DF, (2008) Type I interferon as a stimulus for cross-priming. Cytokine Growth Factor Rev 19: 33-40.
29. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, et al. (2001) Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14: 461-470.
30. Lapenta C, Santini SM, Logozzi M, Spada M, Andreotti M, et al. (2003) Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med 198: 361-367.
31. Parlato S, Romagnoli G, Spadaro F, Canini I, Sirabella P, et al. (2010) LOX-1 as a natural IFN-alpha-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. Blood 115: 1554-1563.
32. Farkas A, Kemeny L, (2011) Interferon-alpha in the generation of monocyte-derived dendritic cells: recent advances and implications for dermatology. Br J Dermatol 165: 247-254.
33. Vermi W, Fisogni S, Salogni L, Scharer L, Kutzner H, et al. (2011) Spontaneous regression of highly immunogenic Molluscum contagiosum virus (MCV)-induced skin lesions is associated with plasmacytoid dendritic cells and IFN-DC infiltration. J Invest Dermatol 131: 426-434.
34. Lechmann M, Berchtold S, Hauber J, Steinkasserer A, (2002) CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol 23: 273-275.
35. Padovan E, Spagnoli GC, Ferrantini M, Heberer M, (2002) IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol 71: 669-676.
36. Santini SM, Lapenta C, Donati S, Spadaro F, Belardelli F, et al. (2011) Interferon-alpha-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12. PLoS One 6: e17364.
37. Kerrigan AM, Brown GD, (2009) C-type lectins and phagocytosis. Immunobiology 214: 562-575.
38. Arredouani M, Yang Z, Ning Y, Qin G, Soininen R, et al. (2004) The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles. J Exp Med 200: 267-272.
39. Wermeling F, Chen Y, Pikkarainen T, Scheynius A, Winqvist O, et al. (2007) Class A scavenger receptors regulate tolerance against apoptotic cells, and autoantibodies against these receptors are predictive of systemic lupus. J Exp Med 204: 2259-2265.
40. Gorgani NN, He JQ, Katschke KJ Jr, Helmy KY, Xi H, et al. (2008) Complement receptor of the Ig superfamily enhances complement-mediated phagocytosis in a subpopulation of tissue resident macrophages. J Immunol 181: 7902-7908.
41. Helmy KY, Katschke KJ Jr, Gorgani NN, Kljavin NM, Elliott JM, et al. (2006) CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124: 915-927.
42. Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL, et al. (1998) Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 392: 505-509.
43. Jaks E, Gavutis M, Uze G, Martal J, Piehler J, (2007) Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 366: 525-539.
44. Uze G, Di Marco S, Mouchel-Vielh E, Monneron D, Bandu MT, et al. (1994) Domains of interaction between alpha interferon and its receptor components. J Mol Biol 243: 245-257.
45. Eisen MB, Spellman PT, Brown PO, Botstein D, (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.
46. Quah BJ, Warren HS, Parish CR, (2007) Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc 2: 2049-2056.